Serelaxin: a potential new drug for the treatment of acute heart failure

Bibliography

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-292
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147-239
   PubMed Web of Science ®Google Scholar
• Teerlink JR. Treatment of acutely decompensated heart failure. In: Greenberg BH, Barnard DD, Narayan SM, Teerlink JR, editors. Management of heart failure. John Wiley & Sons, USA; 2010. p. 327-56
   Google Scholar
• Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112(25):3958-68
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149(2):209-16
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Jones MI, Allan TF, et al. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J 2000;21(22):1877-87
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004;148(1):43-51
   PubMed Web of Science ®Google Scholar
• Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363(15):1419-28
   PubMed Web of Science ®Google Scholar
• Felker GM, Pang PS, Adams KF, et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010;3(2):314-25
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Greene SJ, Ambrosy AP, et al. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 2013;10(2):85-97
   PubMed Web of Science ®Google Scholar
• Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013;19(6):371-89
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381(9860):29-39
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Felker GM, Ahmad T, et al. Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J 2013;166(4):629-35
   PubMed Web of Science ®Google Scholar
• Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don’t. Heart Fail Rev 2009;14(4):299-307
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Alburikan K, Metra M, Rodgers JE. Acute decompensated heart failure update. Curr Cardiol Rev 2013. [ Epub ahead of print]
   Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364(9):797-805
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343(4):246-53
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287(12):1531-40
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365(1):32-43
   PubMed Web of Science ®Google Scholar
• Chen HH, AbouEzzeddine OF, Anstrom KJ, et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circ Heart Fail 2013;6(5):1087-94
   PubMed Web of Science ®Google Scholar
• Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325(21):1468-75
   PubMed Web of Science ®Google Scholar
• Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999;138(2 Pt 1):247-53
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Jama 2002;287(12):1541-7
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360(9328):196-202
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297(17):1883-91
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1(2):103-11
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011;378(9792):667-75
   PubMed Web of Science ®Google Scholar
• Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011;378(9792):676-83
   PubMed Web of Science ®Google Scholar
• Valentova M, von Haehling S. An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013. Expert Opin Investig Drugs 2014;23(4):573-8
   PubMedGoogle Scholar
• Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010;16(12):922-30
   PubMed Web of Science ®Google Scholar
• Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001(4):Cd002066
   Google Scholar
• Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure – a pilot study. Eur J Heart Fail 2002;4(6):753-6
   PubMed Web of Science ®Google Scholar
• Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008;25(4):205-9
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69
   PubMed Web of Science ®Google Scholar
• Chan LJ, Hossain MA, Samuel CS, et al. The relaxin peptide family--structure, function and clinical applications. Protein Pept Lett 2011;18(3):220-9
   PubMed Web of Science ®Google Scholar
• Bathgate RA, Halls ML, van der Westhuizen ET, et al. Relaxin family peptides and their receptors. Physiol Rev 2013;93(1):405-80
   PubMed Web of Science ®Google Scholar
• Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: the hormone relaxin. Cell Mol Life Sci 2007;64(12):1539-57
   PubMed Web of Science ®Google Scholar
• Miyares MA, Davis KA. Serelaxin, a ‘breakthrough’ investigational intravenous agent for acute heart failure. P T. 2013;38(10):606-11
   Google Scholar
• Bullesbach EE, Schwabe C. Functional importance of the A chain loop in relaxin and insulin. J Biol Chem 1994;269(18):13124-8
   PubMed Web of Science ®Google Scholar
• Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009;14(4):321-9
   PubMed Web of Science ®Google Scholar
• Stewart DR, Celniker AC, Taylor CA Jr, et al. Relaxin in the peri-implantation period. J Clin Endocrinol Metab 1990;70(6):1771-3
   PubMed Web of Science ®Google Scholar
• Johnson MR, Okokon E, Collins WP, et al. The effect of human chorionic gonadotropin and pregnancy on the circulating level of relaxin. J Clin Endocrinol Metab 1991;72(5):1042-7
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Clark CL. Evidence for a novel source of relaxin: atrial cardiocytes. J Endocrinol 1994;143(2):R5-8
   PubMed Web of Science ®Google Scholar
• Hsu SY, Kudo M, Chen T, et al. The three subfamilies of leucine-rich repeat-containing G protein-coupled receptors (LGR): identification of LGR6 and LGR7 and the signaling mechanism for LGR7. Mol Endocrinol 2000;14(8):1257-71
   PubMed Web of Science ®Google Scholar
• Hsu SY, Nakabayashi K, Nishi S, et al. Activation of orphan receptors by the hormone relaxin. Science 2002;295(5555):671-4
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Alexiou K, Kinkel HT, et al. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling. J Card Fail 2011;17(2):158-66
   PubMed Web of Science ®Google Scholar
• Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol 2007;612:65-87
   PubMed Web of Science ®Google Scholar
• Bani-Sacchi T, Bigazzi M, Bani D, et al. Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 1995;116(1):1589-94
   PubMed Web of Science ®Google Scholar
• Conrad KP. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Investig 2004;11(7):438-48
   PubMedGoogle Scholar
• Dschietzig T, Bartsch C, Richter C, et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003;92(1):32-40
   PubMed Web of Science ®Google Scholar
• Novak J, Ramirez RJ, Gandley RE, et al. Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am J Physiol Regul Integr Comp Physiol 2002;283(2):R349-55
   PubMed Web of Science ®Google Scholar
• McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 2011;152(7):2786-96
   PubMed Web of Science ®Google Scholar
• Xu Q, Chakravorty A, Bathgate RA, et al. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension 2010;55(5):1260-6
   PubMed Web of Science ®Google Scholar
• Siryk-Bathgate A, Dabul S, Lymperopoulos A. Current and future G protein-coupled receptor signaling targets for heart failure therapy. Drug Des Devel Ther 2013;7:1209-22
   PubMed Web of Science ®Google Scholar
• Du XJ, Hewitson TD, Nguyen MN, Samuel CS. Therapeutic effects of serelaxin in acute heart failure. Circ J 2014;78(3):542-52
   PubMed Web of Science ®Google Scholar
• Mordenti J, Chen SA, Moore JA, et al. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991;8(11):1351-9
   PubMed Web of Science ®Google Scholar
• Cossum PA, Dwyer KA, Roth M, et al. The disposition of a human relaxin (hRlx-2) in pregnant and nonpregnant rats. Pharm Res 1992;9(3):419-24
   PubMed Web of Science ®Google Scholar
• O’Byrne EM, Brindle S, Quintavalla J, et al. Tissue distribution of injected 125I-labeled porcine relaxin: organ uptake, whole-body autoradiography, and renal concentration of radiometabolites. Ann N Y Acad Sci 1982;380:187-97
   PubMed Web of Science ®Google Scholar
• Cheah SH, Sherwood OD. Target tissues for relaxin in the rat: tissue distribution of injected 125I-labeled relaxin and tissue changes in adenosine 3’,5’-monophosphate levels after in vitro relaxin incubation. Endocrinology 1980;106(4):1203-9
   PubMed Web of Science ®Google Scholar
• Gavino ES, Furst DE. Recombinant relaxin: a review of pharmacology and potential therapeutic use. BioDrugs 2001;15(9):609-14
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15(3):182-90
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373(9673):1429-39
   PubMed Web of Science ®Google Scholar
• Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61(2):196-206
   PubMed Web of Science ®Google Scholar
• Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2014;35(16):1041-50
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014;35(7):431-41
   PubMed Web of Science ®Google Scholar
• Voors AA, Meyer S, Stepinska J, et al. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: main results of a randomized, placebo-Controlled, multiCenter study. Heart Failure Society of America, Orlando, FL, USA; 2013
   Google Scholar